Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics reported on Thursday a 42 percent increase in its fourth quarter revenues on growing sales and reimbursement of its thyroid tests.

For the three-month period ended Dec. 31, Interpace's revenues climbed to $4.4 million from $3.1 million in the same period the year before. Contributing to the increase was the continued expansion of payor coverage for the company's ThyGenX and ThyraMir tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.